Research Article| Volume 98, ISSUE 1, SUPPLEMENT 1, S104-S110, January 16, 1995

The androgenicity of progestins

  • Philip D. Darney
    Requests for reprints should be addressed to Philip D. Darney, M.D., M.Sc., San Francisco General Hospital, 1001 Potrero Avenue, Ward 6D, San Francisco, California 94110.
    From the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      All steroid hormones are structurally similar, but relatively minor differences cause profound alterations in biochemical activity. The 21-carbon series (pregnane nucleus) includes the corticoids and the true progestins (e.g., medroxyprogesterone acetate). The 19-carbon series (androstane nucleus) includes all the androgens, among them the progestins used in most oral and parenteral contraceptives. The removal of carbon 19 from testosterone changes the major hormonal effect from androgenic to progestogenic, but these “19-nor” steroids retain varying degrees of androgenic activity. (They can also have limited estrogenic activity, but this is insignificant at the low doses used for contraception.) Some of the 19-nortestosterone progestins are metabolized to other compounds (e.g., norethynodrel, ethynodiol diacetate, and lynestrenol to norethindrone), and some (levonorgestrel, desogestrel) are active unchanged. The lingering androgenic effects of 19-nor progestins are dose-related, opposed by estrogen, and are manifested metabolically (e.g., glucose tolerance, lipoprotein synthesis) and symptomatically (e.g., acne, weight gain). The effect of 19-nortestosterones on lipoproteins prompted the development of less androgenic compounds, but the obvious benefit of the new progestins (desogestrel, gestodene, norgestimate)is a reduction in the symptoms associated with the androgenicity of the older compounds. Mitigation of androgenic effects on lipoprotein and carbohydrate metabolism could have long-term benefits, especially for women who are at risk of arteriosclerotic vascular disease; however, these effects remain to be epidemiologically demonstrated.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Stanczyk FZ
        • Roy S
        Metabolism of levonorgestrel norethindrone, and structurally related contraceptive steroids.
        Contraception. 1990; 42: 67-96
        • Meade TW
        • Greenberg G
        • Thompson SG
        Progestogens and cardiovascular reac-tions associated with oral contraceptives and a comparison of the safety of 50 and 30-microgram oestrogen preparations.
        Br Med J. 1980; 280: 1157-1161
        • Kay C
        Progestagens and arterial disease—evidence from the Royal College of General Practitioners' study.
        Am J Obstet Gynecol. 1982; 142: 758-761
        • Hirvonen E
        • Idanpaan-Heikkila J
        Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Fin-land from 1975 to 1984.
        Am J Obstet Gynecol. 1990; 163: 281-284
        • Stampfer MJ
        • Willett WC
        • Colditz G
        • Speizer FE
        • Hennekens CH
        A prospective study of past use of oral contraceptive agents and the risk of cardiovascular dis-eases.
        N Engl J Med. 1988; 319: 1313-1317
        • Porter JB
        • Jick H
        • Walker AM
        Mortality among oral contraceptive users.
        Obstet Gynecol. 1987; 70: 29-32
        • Upmalis D
        • Phillips A
        Receptor binding and in vivo activities of the new progestins.
        JSOGC. 1991; 13: 35
        • Fotherby K
        • Caldwell A
        New progestins in oral contraception.
        Contraception. 1994; 49: 1-32
        • Hammond G
        • Langley M
        • Robinson P
        • et al.
        Serum steroid binding protein concen-trations and bioavailability of testosterone with oral contraceptives.
        Fertil Steril. 1984; 42: 44-51
        • Chapdelaine A
        • Desmarais J
        • Derman R
        Clinical evidence of the minimal andro-genic activity of norgestimate.
        Int J Fertil. 1989; 34: 347-352
        • van der Vange J
        • Blankenstein MA
        • Kloosterboer HJ
        • Haspels AA
        • Thijssen JH
        Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin total and free testosterone.
        Contraception. 1990; 41: 345-352
        • Mall-Haefali M
        • Werner-Zodrow I
        • Huber PR
        Biochemical and clinical results with the new micropill Cilest.
        in: Keller PJ Aktuelle Aspekte der Hormonalen Kontrazeption.Bonn, 1991: 53-64
        • Jung-Hoffmann C
        • Heidt F
        • Kuhl H
        Effect of two oral contraceptives containing 30 micrograms ethinyl estradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters.
        Contraception. 1988; 38: 593-603
        • Cullberg G
        • Mattsson L-A
        Androgenic, oestrogenic and antioestrogenic effects of desogestrel and lynestrenol alone: effects of serum proteins, sex hormones and vaginal cytology.
        in: Harrison RF Thompson W Bonnar J Trends in Oral Contraception. Hingham. MTP Press Ltd, Karger Basel1984: 17-24
        • Song S
        • Chen J
        • Lu C
        • et al.
        Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
        Contraception. 1993; 47: 527-537
        • Bergink E
        • Van Meel F
        • Turpijn E
        • van der Vies J
        Binding of progestogens to receptor proteins in MCF-7 cells.
        J Steroid Biochem. 1983; 19: 1563-1570
        • Refn H
        • Kjaer A
        • Lebech A
        • Borggaard B
        • Schiefup L
        Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene.
        Contraception. 1990; 41: 259-269
        • Song S
        • Chen J
        • Yang P
        • et al.
        A cross-over study of three oral contraceptives containing ethinyl oestradiol and either desogestrel or levonorgestrel.
        Contraception. 1992; 45: 523-532
        • Palatsi R
        • Hirvensalo E
        • Liukko P
        • et al.
        Serum total and unbound testosterone and sex hormone binding globulin in female acne patients treated with two different oral contraceptives.
        Acta Derm Venereol (Stockh). 1984; 64: 517-523
        • Kloosterboer HJ
        • van Wayjen R
        • van den Ende A
        Effects of three low-dose oral contraceptive combinations on sex hormone binding globulin, corticosteroid binding globulin and antithrombin III activity in healthy women: two monophasic desogestrel combinations (containing 0.020 or 0.030 mg ethinyl estradiol) and one triphasic levonorgestrel combination.
        Acta Obstet Gynecol Scand Suppl. 1987; 144: 41-44
        • Grunwald K
        • Rabe T
        • Runnebaum R
        Clinical tolerance of a low-dose norgestimate-containing combination oral contraceptive (Cilest) in a West Germany multicenter study (Heidelberg Multicenter Oral Contraceptive Study).
        in: Keller PJ Aktuelle Aspekte der Hormonalen Kontraception. Bonn, 1991: 67-78
        • Geissler K
        • Ballmer F
        Influence of a combination of desogestrel and ethinyl estradiol on acne vulgaris in women seeking contraception; results of an open non-comparative, multicenter trial.
        TW Gynaekol. 1989; 2: 321-324
        • Bilotta P
        • Favilli S
        Clinical evaluation of a monophasic ethinyl estradiol/ desogestrel-containing oral contraceptive.
        Arzneimittelforschung. 1988; 38: 932-934
        • Cullberg G
        • Hamburger L
        • Mattsson L
        • et al.
        Effects of desogestrel/ethinyl estra-diol in hirsutism and rogens and SHBG.
        Acta Obstet Gynecol Scand. 1985; 64: 195-202
        • Porcile A
        • Gallardo E
        Oral contraceptives containing desogestrel in hirsutism.
        Contraception. 1991; 44: 533-540
        • Venturoli S
        • Porcu E
        • Gammi L
        • et al.
        The effects of desogestrel and ethinylestra-diol combination in normal and hyperandrogenic young girls: speculations on contra-ception in adolescence.
        Acta Eur Fertil. 1988; 19: 129-134
        • Nappi C
        • Leone F
        • Nicotra A
        • et al.
        Effect of desogestrel with 20 or 30 micrograms ethinyl estradiol in adolescents with hyperandrogenism.
        in: Genassi A Petraglia F Volpe A Progress in Gynecology and Endocrinology. Parthenon Publishing Group, Carnforth1990: 757-764
        • Sobrio G
        • Granata H
        • Granese D
        • et al.
        SBHG, CBG and ceruloplasmin changes with two low dose oral contraceptives.
        Clin Exp Obstet Gynecol. 1991; 18: 43-45
        • Runnebaum B
        • Grunwald K
        • Rabe T
        The efficacy and olerability of norgestimate/ ethinyl estradiol: results of an open multicenter study of 59, 701 women.
        Am J Obstet Gynecol. 1992; 166: 1963-1968
        • Corson SL
        Efficacy and clinical profile of a new oral contraceptive containing norgestimate: U.S. clinical trials.
        Acta Obstet Gynecol Scand Suppl. 1990; 152: 25-31
        • Hoppe G. Gestodene
        an innovative progestin.
        Contraception. 1988; 37: 29-44
        • Affandi B
        • Cekan S
        • Boonkasemanti F
        • Samil R
        • Dicsfalsuy E
        The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive.
        Contraception. 1987; 35: 135-143
        • Darney P
        • Klaisle C
        • Tanner S
        • Alvarado A
        Sustained release contraceptives.
        Curr Prob Obstet Gynecol Fertil. 1990; 13: 87-121
        • Olsson S
        • Odlind V
        • Johansson E
        Clinical results with subcutaneous implants containing 3-ketodesogestrel.
        Contraception. 1990; 42: 1-11
        • Patsch W
        • Brown S
        • Gotto A
        • et al.
        The effect of triphasic oral contraceptives on plasma lipids and lipoproteins.
        Am J Obstet Gynecol. 1989; 161: 1396-1401
        • Ball M
        • Ashwell E
        • Jackson M
        • Gillmer M
        Comparison of two triphasic contracep-tives with different progestogens: effects on metabolism and coagulation proteins.
        Contraception. 1990; 41: 363-373
        • Refn H
        • Kjaer A
        • Lebech A
        • Borggaard B
        • Schierup L
        • Bremmelgaard A
        Meta-bolic changes during treatment with two different progestogens.
        Am J Obstet Gyne-col. 1990; 163: 374-377
        • Weber-Diehl F
        • Lehnert J
        • Lachnit U
        Comparison of two triphasic oral contracep-tives containing either gestodene or norethindrone: a randomized controlled trial.
        Contraception. 1993; 48: 291-301
        • Janaud A
        • Rouffy J
        • Upmalis D
        • Dain MP
        A comparison study of lipid and andro-gen metabolism with triphasic oral contraceptive formulations containing norgest-imate of levonorgestrel.
        Acta Obstet Gynecol Scand Suppl. 1992; 156: 33-38
        • Kirkman RJ
        • Pedersen JH
        • Fioretti P
        • Roberts HE
        Clinical comparison of two low-dose oral contraceptives, Minulet Mercilon, in women over 30 years of age.
        Contraception. 1994; 49: 33-46
        • Anderson F
        Selectivity and minimal androgenicity of norgestimate in mono-phasic and triphasic oral contraceptives.
        Acta Obstet Gynecol Scand. 1992; 71: 15-21
        • Rekers H
        Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
        Acta Obstet Gynecol Scand. 1988; 67: 171-174
        • Dusterberg B
        • Brill K
        Clinical acceptability of monophasic gestodene.
        Am J Obstet Gynecol. 1990; 163: 1398-1404
        • Darney P
        Efficacy and safety of triphasic DSG/EE.
        Contraception. 1993; 48: 323-337
        • Cullberg G
        • Samsioe G
        • Andersen RF
        • et al.
        Two oral contraceptives, efficacy serum proteins lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.
        Contraception. 1982; 26: 229-243